"Quiénes Somos El Instituto de Investigaciones Clínicas Mar del Plata, está formado por investigadores clínicos que poseen conocimientos e instrumentos para entender, descubrir, tratar y prevenir una amplia variedad de enfermedades. El IIC MDP une a investigadores, pacientes y comunidad a través de la ciudad y la zona para potenciar y compartir los recursos de la investigación a través de la conducción de Estudios de Investigación Clínica."

During the past decade, Instituto de Investigaciones Clinicas-Mar del Plata conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 23 clinical trials were completed, i.e. on average, 47.9% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 20 clinical trials were completed. i.e. 74.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas-Mar del Plata" #1 sponsor was "Eli Lilly and Company" with 13 trials, followed by "Gilead Sciences" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas-Mar del Plata" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Medidata Solutions" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator and "AcitGraph" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Investigaciones Clinicas-Mar del Plata" are "Rheumatoid Arthritis" (7 trials), "Hypertension" (4 trials), "Pulmonary Hypertension" (4 trials), "Breast Neoplasms" (3 trials) and "Cardiovascular Diseases" (3 trials). Many other conditions were trialed in "Instituto de Investigaciones Clinicas-Mar del Plata" in a lesser frequency.

Most popular intervention types in "Instituto de Investigaciones Clinicas-Mar del Plata" are "Drug" (52 trials), "Biological" (5 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Tirzepatide" (5 trials), "Abemaciclib" (4 trials), "Adalimumab" (2 trials) and "Darusentan" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Investigaciones Clinicas-Mar del Plata" are 51 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto de Investigaciones Clinicas-Mar del Plata". undefined are not yet recruiting, 14 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 21 completed trials in Instituto de Investigaciones Clinicas-Mar del Plata, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Investigaciones Clinicas-Mar del Plata, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".